The fact that one cell encodes a single antibody sequence does not ne arily mean that the resulting antibody folds into a single structure, although this is a common assumpton. Here we challenge this view and suggest that many antibodies do not have a single conformation at the combining site.
Since Clonal Selection replaced the Instructive Theory as a working model of immunity, the axiom of one-lymphocyteone-antibody has been equated to one combining site (1) (2) (3) (4) . Experiments defining the basis of humoral immune diversity have emphasized combinatorial and somatic mutational processes that lead to covalent diversity of the antibody repertoire (5) . Nevertheless, two independent lines of evidence exist for diversity at the level of antibody tertiary structure. Certain crystal structures of antibodies with and without ligands have shown conformation dimorphism, which could only partly be attributed to crystallization artifacts (6) (7) (8) . Despite the rich detail of these structures, crystallographically detected conformational differences due to ligation are mechanistically ambiguous (9) . Differences could arise from direct interaction with the ligand (induced fit) or, with equal plausibility, by preferential ligand binding to a preexisting subpopulation of antibody isomers. This distinction is of considerable immunological consequence, since two isomers in spontaneous equilibrium would both form part of the humoral repertoire, whereas an induced conformation existing only in an immune complex would not contribute to diversity in the same way. Kinetic analysis avoids this particular ambiguity. Indeed, studies on several myeloma proteins have demonstrated kinetically distinct conformational isomers (10) (11) (12) (13) . It could be argued that myeloma cells have an uncertain ontogeny and are not subject to the immune maturation mechanisms encountered in a bona fide antigenic response; however, similar kinetic behavior was reported for an anti-fluorescein hybridoma (14) . Some of these cases demonstrate a preexisting isomeric equilibrium and others are consistent with an induced-fit mechanism. Notwithstanding this evidence that conformational polymorphism can occur, the isolated examples uncovered through either structural or kinetic approaches leave an uncertainty whether antibody isomerism is an oddity or a general and important factor in an immune response.
Here we address the lack of a context for evaluating the role of isomerism in monoclonal antibodies from hybridomas derived from an immune response. The humoral response to the hapten 2-phenyl-5-oxazolone (Ox) in BALB/c mice is highly reproducible, inasmuch as use of the same canonical variable region (V) genes has been observed repeatedly, often with identical somatic point mutations. Previous reports from our laboratory have described derivation and antibody mRNA sequence analysis of a large number of hybridomas from discrete stages ofthe Ox response (15) (16) (17) (18) (19) (20) . We have also presented an analysis of the hapten-binding kinetics of 40 monoclonal antibodies from this collection (21) . Most of these reactions followed simple first-order kinetics, but three appeared more complex, suggesting the occurrence of an isomerization. Thus some form of conformational diversity was potentially manifest within the context of an extremely well-characterized immune response. Here we report mechanistic analysis of these three molecules and the implication of their shared features.
MATERIALS AND METHODS Antibodies and Haptens. Hybridoma lines NQ10/4.6.2, NQ22/33.4, and NQ22/61.1 have been characterized previously (17, 18) . Antibodies from these cell lines were all IgG1,K type, and they were purified by affinity chromatography on staphylococcal protein A-Sepharose. Ox-aminocaproate (Ox-cap) was synthesized by a published method (22) . Ox (23) to the corresponding expressions for r, the variable for empirical rate constants described below in Eqs. 9, to optimize a common set of true kinetic constants. Because of the extended range in rates, a logarithmic fit was used-i.e., the quantity minimized was (log robrved -log rcawd)2 RESULTS Triphasic Kinetics with Antibody NQ22/61.l. The reaction of Ox-IDA with antibody NQ22/61.1, measured by quenching of antibody fluorescence in a stopped-flow instrument, is shown in Fig. 1 . One phase of the reaction appears to be complete within 20 ms (Fig. 1A) . However, the reaction continues over the following 10 s (Fig. 1B) . This subsequent process is in turn biphasic; attempts to fit later data points to a simple exponential invariably gave systematic deviations in the residuals. Thus the reaction of NQ22/61.1 followed overall triphasic kinetics.
In the initial discovery of antibody isomerism (10), myeloma protein MOPC 460 showed a biphasic interaction with low-affinity ligands, leading to proposal of the following mechanism:
two isomers toward ligand (L) gives rise to complex kinetics, which according to relaxation theory (10, 24) should be triphasic. To our knowledge, no triphasic antibody-hapten reaction has previously been reported. The absence of a third phase in earlier studies (10) (11) (12) (13) (14) has been attributed variously to experimental difficulties in detecting very short relaxation times or low amplitudes, or to the system approximating a limiting case of Mechanism I. The operation of Mechanism I in these cases was inferred from quantitative incongruities in other parameters, such as independently measured equilibrium constants or relaxation amplitudes.
Kineic Theory of Mechanism I. Our stopped-flow experiments initiate from separate reactants, rather than from a point near equilibrium, hence relaxation theory (10, 24) is not strictly applicable. Here we present a different treatment, which employs the approximation that the concentration of a ligand present in great excess is effectively constant over the course of a reaction, but which otherwise is exact. Mechanism I can be described by a system of four linear homogeneous first-order differential equations: [3] d
. [4] When this system is solved by matrix methods, three nonzero eigenvalues arise, again leading to prediction of a triphasic reaction. At a given ligand concentration, L, these are equal to the three roots, r, of the cubic equation r3+ r2(k + kL1 + k2L + k2 +k3+ k+3+ k4L +kL4) + r(kLk4L + k1k2L + k2k4L2 + k2kL4 + k3kL4 + k_2k3 + klk4 +k2kL4L + kLk4 +k-lk3+ k2k3L + klk3+ k3k4L + k-lk-2+ klk-2+k-2k4L + k-lk-3+ k2k-3L + k1k-3 + L3k34L) + klk2kL4L + kLk3k4L + klk2k3L + k2k3k4L2 + kLkL2k4L + k-lk_3k4L + klk2k-3L + k2kL3k4L2 + k-lk-2k-4 + k-lk3kL4 + klk2k3 + k2kL3kL4L + klk-2k-4 + klk_3kL4 + klk -2k3 + k_2k3k4L = 0. [51 To calculate the cubic roots (25) we assign simplifying coefficients of the form r3 + a1r2 + a2r + a3 = 0 [6] and substitute Q = {al -3a2}"2/3 [7] and 2al -9ala2 + 27a3 = arccos 4Q3 54Q [8] The F(t) = Flexp(-rot) + F2exp(-r&+2Xt) + F3exp(-rO+4-,t). [10] Here, the amplitudes F1, F2, and F3 are measured experimentally, but they cannot be derived without assumptions of the fluorescence quantum yield of the individual steps in Mechanism I.
Consistency of NQ22/61.1 with Mechanism I. To determine whether NQ22/61.1 could follow this model, we measured kinetics of reaction with Ox-IDA over a range of hapten concentrations. The apparent rate constants of the three phases are plotted in Fig. 2 (27) . However, reactions of the antibodies with Ox derivatives with symmetrical amino or iminodiacetate side chains still showed multiphasic kinetics (Figs. 1-3 ), eliminating this possibility. Thus the complex kinetics of these antibodies appears intrinsic to antigen recognition. DISCUSSION Our kinetic analysis demonstrates that the three Ox antibodies studied all exist in an equilibrium between isomeric states. The data do not allow us an accurate estimation of the molar ratios of both isomers. However, the roughly equivalent fluorescence amplitudes of the fast and slow phases indicate that a substantial proportion of each species makes up this equilibrium in the absence of antigen. Although Mechanism I formally includes an induced-fit component, NQ22/33.4 and NQ10/4.6.2 approach a limiting case of this mechanism, in which this component is negligible, while high-affinity binding to Ab* represents the major pathway of antigen recognition. That these observations arise in the context of an immune response whose repertoire evolution has been extensively mapped at the sequence level enables us to add two conclusions that could not be drawn from earlier kinetic and crystallographic studies. First, antibody isomerism is not rare: our three examples are from a total ofjust 40 Ox-specific hybridomas. Furthermore, these three antibodies use distinct combinations of light and heavy chain V-gene families. NQ10/4.6.2 (VK45 and M21), NQ22/33.4 (VK45 and group 6), and NQ22/61.1 (Oxl and M21), showed different pairings, thus the three molecules in this study are distinct structures of independent origin. By contrast, many of the remaining antibodies are iterations of the canonical anti-Ox genes, VH-OX1 and Vr-Ox1. Given the multiplicity of occurrence and the improbability that the anti-Ox response represents a special case, it may be valid to extrapolate that a tenth of all antibodies show this form of isomerism. However, isomerism may be more general. The phenomenon cannot be detected by equilibrium techniques, nor do kinetic techniques guarantee detection of isomeric equilibria, as the magnitude of rate constants or amplitudes could easily give the appearance of a simple binding mechanism. Thus isomerism detected by kinetic data may represent only the tip of an iceberg.
We conclude, second, that, rather than being eliminated during immune maturation, lymphocytes expressing isomeric antibodies compete effectively with other lymphocytes, even in hyperimmune responses. One antibody (NQ10/4.6.2) originates from the secondary immune response, and the other two from the tertiary. Sequence data show that each has undergone somatic mutation. The Vr-Oxl-derived light chain of NQ22/61.1, for example, has seven protein-coding mutations relative to the germ-line sequence, including characteristic mutations at residues 34 and 36. Mutations at these sites are found in nearly all Ox-specific VK-Ox1 derivatives, and the side chains at these positions have been shown in a crystal structure to interact directly with hapten (28) . The hapten affinities of the three isomeric molecules show between 3-and 18-fold-enhanced hapten affinity compared with the unmutated canonical Ox antibody (17, 18, 21) . Such increases are not particularly high for the secondary and tertiary responses, but this in part may be attributed to the energetic cost of isomerization. Furthermore, the antibody with the weakest affinity, NQ22/61.1, shows a very high hapten association rate constant (on-rate) for one of its isomers; we have argued previously that a fast on-rate is a physical property of significant selective value during immune maturation (21) .
Structural differences distinguishing the anti-Ox conformations, whatever they may be, clearly are sufficient that only one isomer binds a specific antigen well. However, an inactive isomer could in principle be the preferred receptor for a second antigen of substantially different structure. The implication for immune diversity of antibodies with potential multiple antigen specificity due to conformational isomers is that the number of lymphocytes in an animal does not limit the available repertoire.
The existence of a combining site in multiple conformations invites several predictions. First, antibodies in the primary repertoire may be more prone to isomerism. Indeed, evolution may favor V genes likely to display such behavior to increase diversity. Second, while we consider only isomerism between two configurations, a more complex picture is likely in at least some examples. Third, isomers which occur in approximately equal molar ratios are easier to detect but not likely to represent the most common pattern. However, a very disfavorable isomeric equilibrium, which will decrease the effective affinity, may still allow B-cell proliferation.
Affinity maturation in such cases may include mutations leading to a more favorable isomeric equilibrium. Indeed, we cannot exclude the possibility that the mature antibodies described in this paper did not originate from primary antibodies with a much less favorable equilibrium. Fourth, mutations responsible for such alterations in the isomeric equilibrium could increase affinity without modification of the combining site itself. Fifth, isomerism could potentiate a type of cross-reactivity in which an antibody conformational change mediates recognition of dissimilar antigens, in effect yielding a bispecific antibody.
